Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 54 out of 100. Mild cognitive impairment

Topic: Amyloid, tau and blood-test diagnosis

Patients with mild cognitive impairment (MCI) were assessed, and a metabolic profile associated with conversion to AD at 18-month follow-up was sought. As compared with nonconverters (n = 10), converters (n = 7) had lower fluorodeoxyglucose uptake in the right temporoparietal cortex (p = 0.02, corrected for cluster size), without individual overlap. Awaiting replication in an independent sample, these findings suggest that among patients with MCI, fluorodeoxyglucose PET may accurately identify rapid converters.

Why it matters

Among patients with mild cognitive impairment, 7 who converted to Alzheimer's disease within 18 months had lower FDG PET glucose uptake in the right temporoparietal cortex than 10 who did not. The authors say FDG PET may identify rapid converters, pending replication.

How this study scored 54/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence left out, no data; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomised / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 4 of 6; Cited by studies here 0 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record 3 of 3; Multi-centre collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 51 of the 95 points it could be judged on, which is 54 of 100. Total 54 of 100.51 of the 95 points we could judge = 54 of 100

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 51 of the 95 points we could judge it on, which is 54 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence — / 5 No evidence rating recorded — left out of this score
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2003 — older than 20 years, still counted
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 604 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 24.2 citations a year over 25 year(s) since 2003
Impact for its field and year 4 / 6 Cited 18.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 2 / 4 Cited 19 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Jean‐Claude Baron: h-index 117 (OpenAlex, whole career)
Institution's track record 3 / 3 Centre National de la Recherche Scientifique: institution h-index 2,511 (OpenAlex)
Multi-centre collaboration 2 / 3 OpenAlex lists 7 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 12707450)
Free to read 0 / 2 Behind a paywall — scores zero
Points 51 / 95 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 51 of the 95 points we could judge it on is 54 out of 100.
Total 54 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

APA 7th

Chételat, G., Desgranges, B., de La Sayette, V., Viader, F., Eustache, F., & Baron, J. (2003). Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology. https://doi.org/10.1212/01.wnl.0000055847.17752.e6

Vancouver

Chételat G, Desgranges B, de La Sayette V, Viader F, Eustache F, Baron J. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology. 2003. doi:10.1212/01.wnl.0000055847.17752.e6. PMID: 12707450.

BibTeX

@article{chetelat2003-12707450,
  author  = {Chételat, Gaël and Desgranges, Béatrice and de La Sayette, Vincent and Viader, Fausto and Eustache, Francis and Baron, Jean‐Claude},
  title   = {{Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?}},
  journal = {Neurology},
  year    = {2003},
  doi     = {10.1212/01.wnl.0000055847.17752.e6},
  pmid    = {12707450},
  url     = {https://doi.org/10.1212/01.wnl.0000055847.17752.e6}
}

Related studies in Mild cognitive impairment

Also tagged “classification”

835 studies in the library carry the topic tag “classification”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 835 tagged studies.

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →